GSTO1 and inflammatory bowel disease: Compared to healthy tissues that display the highest positivity level (38.79 ± 7.14%), GSTO1 expression gradually and significantly decreases in IBD (26.79 ± 3.42%, P < 0.01), in adenomas (17.70 ± 2.19%, P < 0.001) and in cancer (14.55 ± 1.87%, P < 0.001) (Figure 2A).